Skip to content

The research snapshot

Every canine CBD study, graded honestly

Eight studies, 1,386 dogs, zero spin. We grade each for design quality and relevance to anxiety — including the trial that failed, because you deserve to see that one too.

Research snapshot

0

studies reviewed

0

placebo-controlled

0

dogs total

0

outcomes graded

Outcomes at a glance

A — Strong: multiple controlled trials agreeB — Promising: at least one good placebo-controlled trialC — Weak or mixed: controlled evidence failed or conflictsI — Insufficient: surveys and anecdotes only

The study library

Chronological by weight of evidence. Every card links to the original journal — read them yourself; that's the point.

Separation & car-travel stress

B

A single dose of cannabidiol (CBD) positively influences measures of stress in dogs during separation and car travel

Hunt, Flint, Logan & King · Frontiers in Veterinary Science · 2023

n = 40 Placebo-controlled, blinded crossover 4 mg/kg, single dose

A single 4 mg/kg dose before separation and car-travel tests reduced several stress indicators (including serum cortisol and stress-related behaviors) versus placebo. Effects were modest and measure-dependent — not a sedative-style knockout.

Read the study

Noise & fireworks fear

C

The impact of feeding cannabidiol (CBD) containing treats on canine response to a noise-induced fear response test

Morris et al. · Frontiers in Veterinary Science · 2020

n = 32 Placebo-controlled, randomized ~1.4 mg/kg (treats)

CBD treats alone did NOT significantly reduce measured fear responses to noise versus placebo. An honest negative: the fireworks use-case has the weakest supporting evidence, and dose/format may matter.

Read the study

Shelter stress & aggression

B-

Cannabis sativa L. may reduce aggressive behaviour towards humans in shelter dogs

Corsetti et al. · Scientific Reports · 2021

n = 24 Controlled, shelter population Titrated CBD oil, daily

Shelter dogs receiving CBD showed reduced aggressive behavior toward humans versus control. Stress behaviors overall didn't change significantly — a real but narrow effect in a high-stress population.

Read the study

Pain & comfort (context)

B

Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs

Gamble et al. (Cornell) · Frontiers in Veterinary Science · 2018

n = 22 Randomized, placebo-controlled, double-blind crossover 2 mg/kg twice daily

The landmark Cornell trial: 2 mg/kg twice daily significantly reduced pain scores and increased activity in osteoarthritic dogs, with no observed serious adverse effects. Pain, not anxiety — but it anchors dosing and safety.

Read the study

Safety & tolerability

A-

Preliminary investigation of the safety of escalating cannabinoid doses in healthy dogs

Vaughn, Kulpa & Paulionis · Frontiers in Veterinary Science · 2020

n = 20 Placebo-controlled dose escalation Up to ~62 mg/kg (escalating)

CBD-dominant oil was well tolerated even at doses far above anything used for anxiety; the most common findings were mild GI upset and elevated ALP liver values at high doses — the reason vets monitor liver enzymes.

Read the study

Safety & tolerability

A-

Long-term daily feeding of cannabidiol is well-tolerated by healthy dogs

Bradley et al. · Frontiers in Veterinary Science · 2022

n = 40 Randomized, placebo-controlled, 6 months 4 mg/kg daily, 26 weeks

Six months of daily 4 mg/kg CBD was well tolerated; ALP elevations occurred in some dogs without clinical signs. The best long-term safety data we have.

Read the study

Pharmacokinetics (dogs & cats)

B-

Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats

Deabold et al. · Animals · 2019

n = 8 Pharmacokinetic study 2 mg/kg twice daily

Established absorption and 12-week safety basics in dogs AND cats — the study most cat guidance leans on. Cats absorbed less and cleared faster than dogs.

Read the study

Owner-perceived calm

I

Owner-reported outcomes with hemp-derived CBD in dogs

Kogan et al. · AHVMA Journal (owner surveys) · 2020

n = 1200 Survey (no placebo control) Varied

Large owner surveys consistently report perceived calming benefit — but owner perception is exactly what placebo effects inflate. We treat surveys as demand signal, not evidence.

Read the study

How we grade

A grade reflects two things: design quality (placebo control, blinding, sample size, objective measures like cortisol vs. owner impressions) and relevance to anxiety (a pain trial can anchor safety and dosing, but can't earn an A for anxiety). Surveys get an I no matter how large — owner perception is exactly what placebo inflates.

When new trials publish, grades change. That is a feature. The "last research review" date in the footer is real — the method is documented here.

Written from primary literature by the research desk Every claim cited & graded Updated July 6, 2026 8 references
/// read the primary source /// placebo control or it didn't happen /// grades change when evidence does